The Use of Direct Thrombin Inhibitors in Cardiovascular Surgery in Patients with Heparin-Induced Thrombocytopenia

One of the most important adverse drug reactions that physicians encounter is the life- and limb-threatening prothrombotic syndrome known as heparin-induced thrombocytopenia (HIT). Unfractionated heparin (UFH), administered during cardiopulmonary bypass (CPB), is highly immunogenic. Heparin-dependent antibodies can develop in 25 to 50% of UFH-treated cardiac surgery patients within 5 to 10 days. These antibodies can activate platelets and are considered the causative agents of HIT. HIT is a relatively common complication, occurring in 1 to 3% of cardiovascular surgery patients when UFH administration is continued postoperatively. It is strongly associated with new thromboembolic events leading to limb amputation and death. In acute or recent (< 100 days) HIT, alternative anticoagulatory regimens are needed during CPB surgery for prevention of HIT-related thrombosis. Treatment options for such patients now generally include the use of alternative anticoagulants such as lepirudin, bivalirudin, or danaparoid, as well as a combined treatment with platelet-function inhibitors and heparin. In patients with a history of HIT and no detectable antibodies, heparin is currently the safest approach for high-dose anticoagulation during CPB. Before and after surgery, however, alternative anticoagulants should be used. The risk of clinical HIT after heart surgery could potentially be reduced by using low-molecular-weight heparins for postsurgery anticoagulation.

Anticoagulation - cardiopulmonary bypass - lepirudin - HIT - thrombocytopenia

REFERENCES

• 1 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost. 1998;  79 1-7
• 2 Koster A, Hansen R, Kuppe H. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients.  J Cardiothorac Vasc Anesth. 2000;  14 243-248
• 3 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  For the ARG-911 Study Investigators. Circulation. 2001;  103 1838-1843
• 4 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin.  Circulation. 2001;  103 1479-1484
• 5 McKeage K, Plosker G L. Argatroban.  Drugs. 2001;  61 515-522
• 6 Chong B H, Magnani H N. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia, 3rd ed. New York; Marcel Dekker 2004: 371-396
• 7 Walls J T, Curtis J J, Silver D. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition.  Ann Thorac Surg. 1992;  53 787-791
• 8 Walls J T, Boley T M, Curtis J J, Silver D. Heparin-induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery.  ASAIO J. 1992;  38 M574-M576
• 9 Glock Y, Szmil E, Boudjema B et al.. Cardiovascular surgery and heparin-induced thrombocytopenia.  Int Angiol. 1988;  7 238-245
• 10 Singer R L, Mannion J D, Bauer T L, Armenti F R, Edie R N. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass.  Chest. 1993;  104 1436-1440
• 11 Pouplard C, May M A, Regina S et al.. Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies.  Blood. 2002;  100 16A-17A
• 12 Warkentin T E, Sheppard J A, Horsewood P et al.. Impact of the patient population on the risk for heparin-induced thrombocytopenia.  Blood. 2000;  96 1703-1708
• 13 Trossaert M, Gaillard A, Commin P L et al.. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery.  Br J Haematol. 1998;  101 653-655
• 14 Bauer T L, Arepally G, Konkle B A et al.. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.  Circulation. 1997;  95 1242-1246
• 15 Francis J L, Palmer III G J, Moroose R et al.. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery.  Ann Thorac Surg. 2003;  75 17-22
• 16 Warkentin T E, Heddle N M. Laboratory diagnosis of immune heparin-induced thrombocytopenia.  Curr Hematol Rep. 2003;  2 148-157
• 17 Warkentin T E. Pork or beef?.  Ann Thorac Surg. 2003;  75 15-16
• 18 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 3rd ed. New York; Marcel Dekker 2004: 107-163
• 19 Warkentin T E, Roberts R S, Hirsh J, Kelton J G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.  Arch Intern Med. 2003;  163 2518-2524
• 20 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344 1286-1292
• 21 Lubenow N, Kempf R. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or re-exposure to heparin.  Chest. 2002;  122 37-42
• 22 Rice L, Attisha W K, Drexler A, Francis J L. Delayed-onset heparin-induced thrombocytopenia.  Ann Intern Med. 2002;  136 210-215
• 23 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis.  Ann Intern Med. 2001;  135 502-506
• 24 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121 535-555
• 25 Martin J F, Daniel T D, Trowbridge E A. Acute and chronic changes in platelet volume and count after cardiopulmonary bypass-induced thrombocytopenia in man.  Thromb Haemost. 1987;  57 55-58
• 26 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
• 27 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 28 Greinacher A, Warkentin T E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 3rd ed. New York; Marcel Dekker 2004: 335-370
• 29 Hong A P, Cook D J, Sigouin C S, Warkentin T E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia.  Blood. 2003;  101 3049-3051
• 30 Lubenow N, Eichler P, Albrecht D et al.. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature.  Thromb Res. 2000;  100 115-125
• 31 Warkentin T E. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia.  Arch Pathol Lab Med. 2002;  126 1415-1423
• 32 Wallis D E, Workman D L, Lewis B E. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.  Am J Med. 1999;  106 629-635
• 33 Warkentin T E, Elavathil L J, Hayward C P. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med. 1997;  127 804-812
• 34 Selleng S, Lubenow N, Wollert H G, Mullejans B, Greinacher A. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin.  Ann Thorac Surg. 2001;  71 1041-1042
• 35 Pötzsch B, Klovekorn W P, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.  N Engl J Med. 2000;  343 515
• 36 Olinger G N, Hussey C V, Olive J A, Malik M I. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation.  J Thorac Cardiovasc Surg. 1984;  87 673-677
• 37 Lewis B E, Matthai Jr W H, Cohen M, Moses J W, Hursting M J, Leya F. Arg-216/310/311 Study Investigators . Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
• 38 Campbell K R, Mahaffey K W, Lewis B E et al.. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.  J Invasive Cardiol. 2000;  12(suppl F) 14F
• 39 Olbricht K, Wiersbitzky M, Wacke W et al.. Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (lepirudin).  Blood Coagul Fibrinolysis. 1998;  9 273-277
• 40 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery.  Ann Thorac Surg. 2003;  76 2121-2131
• 41 Warkentin T E, Dunn G L, Cybulsky I J. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia.  Ann Thorac Surg. 2001;  72 1730-1732
• 42 Koster A, Kuppe H, Crystal G J, Mertzlufft F. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin.  Anesth Analg. 2000;  90 292-298
• 43 Spiess B D, DeAnda A, McCarthy A. Off-pump CABG in a patient with HITT anticoagulated with bivalirudin: a case report.  Anesth Analg. 2002;  93 SCA70
• 44 Merry A F, Raudkivi P, White H D. Anticoagulation with bivalirudin (a direct thrombin inhibitor) vs heparin.  A randomized trial in OPCAB graft surgery Anesth Analg. 2003;  93 SCA33
• 45 Lincoff A, Bittl J, Harrington R et al.. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.  JAMA. 2003;  289 853-863
• 46 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.  Thromb Res. 2003;  110 73-82
• 47 The Direct Thrombin Inhibitor Trialists’ Collaborative Group . Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data.  Lancet. 2002;  359 294-302
• 48 Greinacher A. Lepirudin: a bivalent direct thrombin inhibiton for anti-coagulation therapy.  Expert Rev Cardiovasc Ther. 2004;  2 339-357
• 49 Refludan® . [package insert] Wayne, NJ; Berlex Laboratories 2002
• 50 Fischer K G. Hirudin in renal insufficiency.  Semin Thromb Hemost. 2002;  28 467-482
• 51 Wittkowsky A K, Kondo L M. Lepirudin dosing in dialysis-dependent renal failure.  Pharmacotherapy. 2000;  20 1123-1128
• 52 Dager W E, White R H. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis.  Ann Pharmacother. 2001;  35 885-890
• 53 Koster A, Merkle F, Hansen R et al.. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems.  Anesth Analg. 2000;  91 265-269
• 54 Bucha E, Kreml R, Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialysers.  Nephrol Dial Transplant. 1999;  14 2922-2926
• 55 Liu H, Fleming N W, Moore P G. Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass.  J Clin Anesth. 2002;  14 452-455
• 56 Pötzsch B, Madlener K, Seelig C et al.. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole-blood ecarin clotting time.  Thromb Haemost. 1997;  77 920-925
• 57 Latham P, Revelis A F, Joshi G P, DiMaio J M, Jessen M E. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass.  Anesthesiology. 2000;  92 263-266
• 58 Despotis G J, Hogue C W, Saleem R et al.. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.  Anesth Analg. 2001;  93 28-32
• 59 Koster A, Loebe M, Hansen R et al.. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the Act II device.  J Thorac Cardiovasc Surg. 2000;  119 1278-1283
• 60 Lindhoff-Last E, Piechottka G P, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level.  Thromb Res. 2000;  100 55-60
• 61 Koster A, Hansen R, Grauhan O et al.. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.  J Cardiothorac Vasc Anesth. 2000;  14 249-252
• 62 Riess F C, Lower C, Seelig C et al.. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful use for aortic valve replacement in man.  J Thorac Cardiovasc Surg. 1995;  110 265-267
• 63 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT).  Circulation. 2003;  108 2062-2065
• 64 Sciulli T M, Mauro V F. Pharmacology and clinical use of bivalirudin.  Ann Pharmacother. 2002;  36 1028-1041
• 65 Koster A, Chew D, Grundel M. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass.  Anesth Analg. 2003;  96 383-386
• 66 Koster A, Chew D, Grundel M et al.. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study.  Anesth Analg. 2003;  96 1316-1319
• 67 Vasquez J C, Vichiendilokkul A, Mahmood S, Baciewicz Jr F A. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.  Ann Thorac Surg. 2002;  74 2177-2179
• 68 Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass.  Ann Thorac Surg. 2003;  75 264-265
• 69 Angiomax® . [package insert] Cambridge, Mass; The Medicines Company 2001
• 70 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
• 71 Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations.  J Thorac Cardiovasc Surg. 2001;  122 1255-1256
• 72 Arnoletti J P, Whitman G J. Heparin-induced thrombocytopenia in coronary bypass surgery.  Ann Thorac Surg. 1999;  68 576-578
• 73 Edwards J T, Hamby J K, Worrall N K. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.  Ann Thorac Surg. 2003;  75 1622-1624
• 74 Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery.  Heart Vessels. 2003;  18 40-42
• 75 Lubenow N, Selleng S, Wollert H G et al.. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use.  Ann Thorac Surg. 2003;  75 577-579
• 76 Gitlin S D, Deeb G M, Yann C, Schmaier A H. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.  J Vasc Surg. 1998;  27 568-575
• 77 Magnani H N, Beijering R JR, ten Cate J W, Chong B H. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA; Hanley & Belfus 1997: 487-500
• 78 Erikson B I, Wille-Jørgensen K, Palebo P et al.. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337 1329-1335